title: [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms].
abstract: OBJECTIVE
  To study the expression and clinical significance of kidney injury molecule-1 (KIM-1) in primary and metastatic renal epithelial neoplasms.
  
  
  METHODS
  A total of 136 cases of kidney neoplasms were retrospectively reviewed including 63 primary clear cell renal cell carcinomas (RCCs), 22 papillary RCCs, 13 chromophobe RCCs, 7 oncocytomas, 7 RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 24 metastatic clear cell RCCs. Immunostaining for KIM-1 and kidney-specific-protein (Ksp)-cadherin were performed and the relationship to tumor stage and grade in clear cell RCCs was investigated.
  
  
  RESULTS
  Expression of KIM-1 was detected in 77.8% (49/63) of clear cell RCCs, 90.9% (20/22) of papillary RCCs, 1/13 of chromophobe RCCs, 7/7 of RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 87.5%(21/24) of the metastatic RCCs, but not detected in 7 cases of oncocytomas. A diffuse expression of KIM-1 was more frequently observed in Furhman nuclear grade III/IV clear cell RCCs (P = 0.010). Ksp-cadherin expression was mainly observed in chromophobe RCCs and oncocytomas.
  
  
  CONCLUSIONS
  KIM-1 is a specific biomarker for injuried kidney proximal tubules and the corresponding neoplasms, and has a high specificity and sensitivity for primary or metastatic clear cell RCCs, papillary RCCs and RCCs associated with Xp11.2 translocation/TFE3 gene fusions. Combination of KIM-1 and Ksp-cadherin immunostaining can lead to a more precise histological classification of primary kidney epithelial neoplasms and improve the diagnostic accuracy of metastatic RCCs.
authors.affiliation: Department of Pathology, Clinical School of Medical College of Nanjing University/Nanjing General Hospital of Nanjing Military Command, People's Liberation Army, China.
authors.forename: Ying-chun
authors.initials: YC
authors.lastname: Dong
authors.forename: Bo
authors.initials: B
authors.lastname: Wu
authors.forename: Jian-dong
authors.initials: JD
authors.lastname: Wang
authors.forename: Qiu
authors.initials: Q
authors.lastname: Rao
authors.forename: Heng-hui
authors.initials: HH
authors.lastname: Ma
authors.forename: Ru-song
authors.initials: RS
authors.lastname: Zhang
authors.forename: Hang-bo
authors.initials: HB
authors.lastname: Zhou
authors.forename: Zhen-feng
authors.initials: ZF
authors.lastname: Lu
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Zhou
mesh_terms: D018249:Adenoma, Oxyphilic / Q000378:metabolism / Q000473:pathology; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000235:genetics / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary; D015820:Cadherins / Q000378:metabolism*; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000473:pathology; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D041321:Chromosomes, Human, X; D050939:Gene Fusion; D000072596:Hepatitis A Virus Cellular Receptor 1; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008175:Lung Neoplasms / Q000378:metabolism / Q000556:secondary; D008562:Membrane Glycoproteins / Q000378:metabolism*; D009375:Neoplasms, Glandular and Epithelial / Q000145:classification / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011991:Receptors, Virus / Q000378:metabolism*; D012189:Retrospective Studies; D014178:Translocation, Genetic
chemical_list: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; C114483:CDH16 protein, human; D015820:Cadherins; C491143:HAVCR1 protein, human; D000072596:Hepatitis A Virus Cellular Receptor 1; D008562:Membrane Glycoproteins; D011991:Receptors, Virus; C069203:TFE3 protein, human